The humanized monoclonal anti-VEGF antibody bevacizumab is the first VEGF-targeting drug, which is officially approved in patients with metastatic colorectal cancer [13], metastatic breast cancer, lung cancer, renal cell carcinomas and glioblastoma multiforme. This evidence concerns the gene VEGFA and glioblastoma.